Bold claim: a single gene variant may determine who avoids chronic rejection after a lung transplant—and this changes how we understand long-term outcomes. But here's where it gets controversial: the relationship between genetics and chronic lung allograft dysfunction (CLAD) is nuanced, and not every patient with the variant experiences trouble. A UCLA Health study suggests that about one-third of lung transplant recipients carry a variant in the C3 gene, which appears to hinder the body's ability to regulate the complement system. This immune pathway normally helps fight infections and clear debris, but when misregulated, it can contribute to chronic rejection of the transplanted lung.
Lung transplants have the lowest long-term survival among solid organ transplants, a reality largely driven by chronic rejection. Dr. Hrish Kulkarni — a leading pulmonary expert and study co-author — emphasizes the goal: to understand why some patients are more vulnerable to chronic rejection and to identify biological pathways that could lead to targeted therapies and ultimately better long-term outcomes.
In the research, two independent cohorts revealed that roughly one-third of participants carried the C3 variant. Across both groups, those with the variant faced higher rates of chronic rejection, particularly when donor-specific antibodies were present. To probe the mechanism, researchers employed a mouse lung transplant model with similar defects in complement regulation. The results pointed to the complement system activating particular B cells, which then produced antibodies attacking the transplanted lung. Importantly, this is a form of rejection that current anti-rejection medications struggle to fully control.
The team’s aim is clear: these insights could spur the development of more personalized therapies for chronic lung rejection, a disease currently without a cure. While the findings are promising, they also raise questions about how to integrate genetic screening into clinical practice and how best to tailor treatments for patients based on their complement system activity.
Source:
Journal reference:
Suggested Reading
Terms
Note: While edited and approved content informs Azthena answers, occasional inaccuracies may occur. Always verify with original sources or authors. This content is informational and not a substitute for professional medical advice. For medical decisions, consult a qualified healthcare provider.
